STOCK TITAN

[Form 4] AETHLON MEDICAL INC Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Chetan Shah, a director of Aethlon Medical, Inc. (AEMD), reported a transaction on 09/30/2025 in which 1,786 shares of common stock were forfeited to cover tax withholdings arising from the conversion of 4,465 vested restricted stock units into common shares. The filing shows a per-share price used for the withholding calculation of $0.749. After the withholding, the reporting person beneficially owned 22,672 shares of common stock. The restricted stock units forfeited were part of a grant previously reported by the reporting person in an earlier Form 4 filed in April 2025.

Chetan Shah, un direttore di Aethlon Medical, Inc. (AEMD), ha riportato una transazione il 30/09/2025 in cui sono stati trattenuti 1.786 azioni comuni per coprire le ritenute fiscali derivanti dalla conversione di 4.465 unità di azioni limitate vestite in azioni comuni. Il deposito mostra un prezzo per azione utilizzato per il calcolo della ritenuta di $0.749. Dopo la trattenuta, la persona che riporta deteneva beneficiariamente 22.672 azioni comuni. Le unità di azioni vincolate rinunciate facevano parte di una concessione precedentemente riportata dalla persona riportante in un precedente Form 4 presentato nell'aprile 2025.

Chetan Shah, un director de Aethlon Medical, Inc. (AEMD), reportó una transacción el 30/09/2025 en la que se cancelaron 1.786 acciones comunes para cubrir las retenciones fiscales derivadas de la conversión de 4.465 unidades de acciones restringidas vestidas en acciones comunes. El escrito muestra un precio por acción utilizado para el cálculo de retenciones de $0.749. Después de la retención, la persona que reporta poseía beneficentemente 22.672 acciones comunes. Las unidades de acciones restringidas canceladas formaban parte de una concesión reportada previamente por la persona en un Form 4 anterior presentado en abril de 2025.

Chetan ShahAethlon Medical, Inc. (AEMD)이사로서, 2025-09-304,465주인수로 vest된 제한주식 유닛의 전환으로 발생한 세금 원천징수를 충당하기 위해 1,786주의 보통주가 몰수되었다고 보고했습니다. 신고 내용에는 원천징수 계산에 사용된 주당 가격이 $0.749로 표시됩니다. 원천징수 후, 보고자는 실질적으로 22,672주의 보통주를 소유하게 되었습니다. 몰수된 제한주식 유닛은 2025년 4월에 보고된 이전 Form 4에서 보고자에 의해 이미 부여된 일부였습니다.

Chetan Shah, un directeur de Aethlon Medical, Inc. (AEMD), a signalé une transaction le 30/09/2025 au cours de laquelle 1.786 actions ordinaires ont été abandonnées pour couvrir les retenues d'impôt résultant de la conversion de 4.465 unités d'actions restreintes acquises en actions ordinaires. Le dépôt indique un prix par action utilisé pour le calcul des retenues de $0.749. Après la retenue, la personne qui déclare détenait bénéficiairement 22.672 actions ordinaires. Les unités d'actions restreintes abandonnées faisaient partie d'une attribution précédemment signalée par la personne déclarant dans un Form 4 déposé en avril 2025.

Chetan Shah, ein Direktor von Aethlon Medical, Inc. (AEMD), meldete am 30.09.2025 eine Transaktion, bei der 1.786 Stammaktien verfallen, um Steuerrückstellungen aus der Umwandlung von 4.465 vesteten Restricted Stock Units in Stammaktien abzudecken. Die Einreichung zeigt einen pro Anteilspreis von $0,749 für die Berechnung der Rückstellungen. Nach der Abführung hielt die meldende Person benefizient 22.672 Stammaktien. Die verfallenen Restricted Stock Units waren Teil einer zuvor von der meldenden Person in einem früheren Form 4 im April 2025 gemeldeten Zuteilung.

تشيتان شاه، مدير في Aethlon Medical, Inc. (AEMD)، أبلغ عن صفقة في 30/09/2025 تم فيها فقدان 1,786 سهم عادي لتغطية الاحتجازات الضريبية الناتجة عن تحويل 4,465 وحدة أسهم مقيدة مكتسبة إلى أسهم عادية. يُظهر الإبلاغ سعرًا للسهم المستخدم في حساب الاحتجاز بقيمة $0.749. بعد الاحتجاز، امتلك المبلغ عنه فعليًا 22,672 سهمًا عاديًا. كانت وحدات الأسهم المقيدة المصادرة جزءًا من منحة ذكرت مسبقًا من قبل المبلغ عنه في نموذج Form 4 السابق في أبريل 2025.

Chetan Shah,一位董事Aethlon Medical, Inc. (AEMD)董事,在2025/09/30报告了一笔交易,其中1,786股普通股被没收以覆盖因将4,465份归属受限股票单位转为普通股而产生的扣缴税款。该披露显示用于扣税计算的每股价格为$0.749。扣缴后,申报人实际拥有22,672股普通股。被没收的受限股票单位属于申报人在2025年4月提交的前一份 Form 4 报告中此前披露的授予的一部分。

Positive
  • None.
Negative
  • None.

Chetan Shah, un direttore di Aethlon Medical, Inc. (AEMD), ha riportato una transazione il 30/09/2025 in cui sono stati trattenuti 1.786 azioni comuni per coprire le ritenute fiscali derivanti dalla conversione di 4.465 unità di azioni limitate vestite in azioni comuni. Il deposito mostra un prezzo per azione utilizzato per il calcolo della ritenuta di $0.749. Dopo la trattenuta, la persona che riporta deteneva beneficiariamente 22.672 azioni comuni. Le unità di azioni vincolate rinunciate facevano parte di una concessione precedentemente riportata dalla persona riportante in un precedente Form 4 presentato nell'aprile 2025.

Chetan Shah, un director de Aethlon Medical, Inc. (AEMD), reportó una transacción el 30/09/2025 en la que se cancelaron 1.786 acciones comunes para cubrir las retenciones fiscales derivadas de la conversión de 4.465 unidades de acciones restringidas vestidas en acciones comunes. El escrito muestra un precio por acción utilizado para el cálculo de retenciones de $0.749. Después de la retención, la persona que reporta poseía beneficentemente 22.672 acciones comunes. Las unidades de acciones restringidas canceladas formaban parte de una concesión reportada previamente por la persona en un Form 4 anterior presentado en abril de 2025.

Chetan ShahAethlon Medical, Inc. (AEMD)이사로서, 2025-09-304,465주인수로 vest된 제한주식 유닛의 전환으로 발생한 세금 원천징수를 충당하기 위해 1,786주의 보통주가 몰수되었다고 보고했습니다. 신고 내용에는 원천징수 계산에 사용된 주당 가격이 $0.749로 표시됩니다. 원천징수 후, 보고자는 실질적으로 22,672주의 보통주를 소유하게 되었습니다. 몰수된 제한주식 유닛은 2025년 4월에 보고된 이전 Form 4에서 보고자에 의해 이미 부여된 일부였습니다.

Chetan Shah, un directeur de Aethlon Medical, Inc. (AEMD), a signalé une transaction le 30/09/2025 au cours de laquelle 1.786 actions ordinaires ont été abandonnées pour couvrir les retenues d'impôt résultant de la conversion de 4.465 unités d'actions restreintes acquises en actions ordinaires. Le dépôt indique un prix par action utilisé pour le calcul des retenues de $0.749. Après la retenue, la personne qui déclare détenait bénéficiairement 22.672 actions ordinaires. Les unités d'actions restreintes abandonnées faisaient partie d'une attribution précédemment signalée par la personne déclarant dans un Form 4 déposé en avril 2025.

Chetan Shah, ein Direktor von Aethlon Medical, Inc. (AEMD), meldete am 30.09.2025 eine Transaktion, bei der 1.786 Stammaktien verfallen, um Steuerrückstellungen aus der Umwandlung von 4.465 vesteten Restricted Stock Units in Stammaktien abzudecken. Die Einreichung zeigt einen pro Anteilspreis von $0,749 für die Berechnung der Rückstellungen. Nach der Abführung hielt die meldende Person benefizient 22.672 Stammaktien. Die verfallenen Restricted Stock Units waren Teil einer zuvor von der meldenden Person in einem früheren Form 4 im April 2025 gemeldeten Zuteilung.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Shah Chetan

(Last) (First) (Middle)
11555 SORRENTO VALLEY ROAD, SUITE 203

(Street)
SAN DIEGO CA 92121

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
AETHLON MEDICAL INC [ AEMD ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/30/2025 F 1,786(1) D $0.749 22,672 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The Reporting Person forfeited 1,786 shares of common stock upon conversion of an aggregate 4,465 vested and outstanding restricted stock units into shares of common stock to cover tax withholdings, using the market price of the issuer's common stock at the time of forfeiture. These restricted stock units were part of the grant reported in Table I of the Form 4 filed by the Reporting Person with the Securities and Exchange Commission on April 25, 2025.
/s/ Chetan Shah, M.D. by: James B. Frakes, Attorney-in-fact 10/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did AEMD director Chetan Shah report on Form 4?

The report discloses the forfeiture of 1,786 common shares to satisfy tax withholdings when 4,465 vested restricted stock units converted into shares.

How many shares does Chetan Shah beneficially own after the transaction?

Following the reported transaction, the reporting person beneficially owned 22,672 shares of AEMD common stock.

What price was used to calculate the tax withholding on the forfeited shares?

The market price used for the withholding calculation was $0.749 per share.

Were the forfeited shares part of a new award?

No; the restricted stock units converted were part of a grant previously reported by the reporting person in a Form 4 filed in April 2025.

What was the transaction date listed for the conversion and forfeiture?

The transaction date shown in the Form 4 is 09/30/2025.
Aethlon Medical

NASDAQ:AEMD

AEMD Rankings

AEMD Latest News

AEMD Latest SEC Filings

AEMD Stock Data

5.28M
7.11M
0.53%
6.03%
30.04%
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
SAN DIEGO